Pricing Log in Create free account

Hemab Therapeutics Holdings, Inc. (COAG) vs Harmony Biosciences Holdings, Inc. (HRMY)

Hemab Therapeutics Holdings, Inc. and Harmony Biosciences Holdings, Inc. are both Biotechnology companies. Hemab Therapeutics Holdings, Inc. is the larger, with a market value of $2.1B against $1.9B — 1.1× the size. Hemab Therapeutics Holdings, Inc. has negative trailing earnings, so its P/E is not meaningful; Harmony Biosciences Holdings, Inc. trades at 10.5×. Harmony Biosciences Holdings, Inc. has the higher net margin (18.1% vs 0.00%) and the higher return on invested capital (30.5% vs 0.00%). Across the 11 metrics below, Harmony Biosciences Holdings, Inc. leads on 9 and Hemab Therapeutics Holdings, Inc. on 2.

Valuation

Metric COAG HRMY Biotechnology median
P/E n/m 10.53 10.26
P/S n/m 1.91 9.18
P/B 3.03 1.76 2.05
Price to free cash flow n/m 6.69 24.81
EV/EBITDA n/m 4.97 0.65
EV/Sales n/m 1.28 8.98
Earnings yield (117.82%) 9.49% (34.89%)
Free cash flow yield (5.28%) 14.94% (24.52%)

Profitability

Metric COAG HRMY Biotechnology median
Gross margin — 74.03% 65.16%
Operating margin 0.00% 22.17% 0.00%
Net margin 0.00% 18.05% 0.00%
Free cash flow margin 0.00% 32.65% 0.00%
Return on equity 0.00% 18.73% (50.12%)
Return on assets (31.79%) 13.30% (45.60%)
Return on invested capital 0.00% 30.45% 0.00%

Growth

Metric COAG HRMY Biotechnology median
Revenue growth (TTM) — 19.79% 6.26%
EPS growth (last fiscal year) — 7.97% 29.88%
Revenue growth, 5-year CAGR — 40.30% 9.75%
Net income growth, 5-year CAGR — 0.00% 0.00%

Health

Metric COAG HRMY Biotechnology median
Debt to equity 0.00 0.14 0.00
Current ratio 35.85 3.44 4.89
Net debt to EBITDA — (2.63) 1.01

Dividend

Metric COAG HRMY Biotechnology median
Dividend yield — — 0.41%
Payout ratio — — —

Size

Metric COAG HRMY Biotechnology median
Market cap 2.13b 1.89b 172.11m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack